Detecting measurable residual disease (MRD) in hematological malignancies using flow cytometry

A patient may be in complete remission during or after a cancer treatment, but a few cancer cells may persist in what is known as residual disease. To better inform prognoses, understand treatment decisions, predict a patient’s overall survival or understand the potential for disease relapse, it is important to have the ability to detect and quantify these malignant cells.

Labcorp completes acquisition of Personal Genome Diagnostics

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 21, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Personal Genome Diagnostics Inc. ( PGDx ), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.